Dr. Jenny C. Chang

Emergency Medicine
281 1st Ave, 
New York, NY 
Clinical Trials:Currently Recruiting for 1 Trial
281 1st Ave, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jenny Chang is an Emergency Medicine provider in New York, New York. Dr. Chang is rated as an Experienced provider by MediFind in Nephrectomy. Her top areas of expertise are Inappropriate Sinus Tachycardia (IST), Aseptic and Alopecic Nodules of Scalp (AANS), Boils, Hepato-Pancreato-Biliary Surgery, and Tissue Biopsy.

Her clinical research consists of co-authoring 208 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Emergency Medicine
Hospital Affiliations
Mount Sinai Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
281 1st Ave, New York, NY 10003

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer
CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer
Enrollment Status: Recruiting
Publish Date: December 15, 2025
Intervention Type: Drug, Radiation
Study Drugs: Letrozole, Palbociclib
Study Phase: Phase 2
Multicenter Phase I/Ib Trial of Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
Multicenter Phase I/Ib Trial of Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 09, 2025
Intervention Type: Drug
Study Drugs: Olaparib, Vorinostat
Study Phase: Phase 1
T-Cell Immune Checkpoint Inhibition Plus Hypomethylation for Locally Advanced HER2-Negative Breast Cancer - A Phase 2 Neoadjuvant Window Trial of Pembrolizumab and Decitabine Followed by Standard Neoadjuvant Chemotherapy
T-Cell Immune Checkpoint Inhibition Plus Hypomethylation for Locally Advanced HER2-Negative Breast Cancer - A Phase 2 Neoadjuvant Window Trial of Pembrolizumab and Decitabine Followed by Standard Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2025
Intervention Type: Drug
Study Drugs: Doxorubicin, Cyclophosphamide, Paclitaxel, Carboplatin, Decitabine, Pembrolizumab
Study Phase: Phase 2
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2025
Intervention Type: Drug
Study Drugs: ONC-392, Pembrolizumab
Study Phase: Phase 1/Phase 2
Multicenter Phase II Trial of Durvalumab (MEDI4736) with Trastuzumab and Pertuzumab Combination in HER2-Enriched and HER2-Amplified Breast Cancer (DTP Trial)
Multicenter Phase II Trial of Durvalumab (MEDI4736) with Trastuzumab and Pertuzumab Combination in HER2-Enriched and HER2-Amplified Breast Cancer (DTP Trial)
Enrollment Status: Active_not_recruiting
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drugs: Durvalumab, Trastuzumab, Pertuzumab
Study Phase: Phase 2
Phase II Study of Docetaxel Chemotherapy With Pembrolizumab and Interleukin-12 Gene Therapy in Patients With Anthracycline- Refractory Triple Negative Breast Cancer (INTEGRAL)
Phase II Study of Docetaxel Chemotherapy With Pembrolizumab and Interleukin-12 Gene Therapy in Patients With Anthracycline- Refractory Triple Negative Breast Cancer (INTEGRAL)
Enrollment Status: Suspended
Publish Date: February 21, 2024
Intervention Type: Drug
Study Drugs: Docetaxel, Doxorubicin, Cyclophosphamide, Pembrolizumab, IL-12 gene therapy, L-NMMA
Study Phase: Phase 2
Phase II Study of The Efficacy And Safety of Chloroquine (C) in CombinAtion With Taxane or Taxane-like (T) Chemo Agents in The Treatment of Patients With Advanced or Metastatic Breast Cancer Who Have Failed Anthracycline Chemo Base Therapy
Phase II Study of The Efficacy And Safety of Chloroquine (C) in CombinAtion With Taxane or Taxane-like (T) Chemo Agents in The Treatment of Patients With Advanced or Metastatic Breast Cancer Who Have Failed Anthracycline Chemo Base Therapy
Enrollment Status: Completed
Publish Date: January 23, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)
Enrollment Status: Completed
Publish Date: September 16, 2022
Intervention Type: Drug
Study Phase: Phase 2
Phase 1/2 Dose-Rising, Safety, Tolerability and Efficacy Study of Topical SOR007 for Cutaneous Metastases
Phase 1/2 Dose-Rising, Safety, Tolerability and Efficacy Study of Topical SOR007 for Cutaneous Metastases
Enrollment Status: Completed
Publish Date: November 05, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
Neoadjuvant Phase II Study Of Everolimus Plus Cisplatin In Triple Negative Breast Cancer Patients With Residual Disease After Standard Chemotherapy
Neoadjuvant Phase II Study Of Everolimus Plus Cisplatin In Triple Negative Breast Cancer Patients With Residual Disease After Standard Chemotherapy
Enrollment Status: Completed
Publish Date: July 20, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Single Arm Study of Palbociclib in Patients With Metastatic HER2-positive Breast Cancer With Brain Metastasis
A Phase II Single Arm Study of Palbociclib in Patients With Metastatic HER2-positive Breast Cancer With Brain Metastasis
Enrollment Status: Terminated
Publish Date: April 14, 2020
Intervention Type: Biological, Procedure, Drug
Study Phase: Phase 2
A Pilot Study: Emotions Immunology and Breast Cancer
A Pilot Study: Emotions Immunology and Breast Cancer
Enrollment Status: Completed
Publish Date: August 28, 2019
Intervention Type: Behavioral, Other
Study Phase: Not Applicable
View 11 Less Clinical Trials

208 Total Publications

Dynamic prognostication of non-muscle invasive bladder cancer using conditional recurrence- and progression-free survival: A SEER-Medicare analysis.
Dynamic prognostication of non-muscle invasive bladder cancer using conditional recurrence- and progression-free survival: A SEER-Medicare analysis.
Journal: Urologic oncology
Published: September 08, 2025
Similar Doctors
Experienced in Nephrectomy
Dr. Joann Hsu
Emergency Medicine
Experienced in Nephrectomy
Dr. Joann Hsu
Emergency Medicine

Queens Emergency Medical Associates PLLC

5645 Main St, 
Flushing, NY 
 (8.2 miles away)
954-939-5000
Languages Spoken:
English
See accepted insurances

Joann Hsu is an Emergency Medicine provider in Flushing, New York. Dr. Hsu is rated as an Experienced provider by MediFind in Nephrectomy. Her top areas of expertise are Respiratory Syncytial Virus (RSV) Infection and Nephrectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chang's expertise for a condition
ConditionClose
        View All 11 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile